Use of progression-free survival (PFS) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective

Malik, S. M. ; Ibrahim, A. ; Sridhara, R. ; Justice, R. L. ; Pazdur, R.

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e18001-e18001 [Periódico revisado por pares]

Texto completo disponível